

## Keytruda® (pembrolizumab) – Expanded indication

- On November 16, 2023, <u>Merck announced</u> the FDA approval of <u>Keytruda (pembrolizumab)</u>, in combination with fluoropyrimidine-and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Keytruda is also approved, in combination with trastuzumab, fluoropyrimidine-and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.
- Refer to the Keytruda drug label for a complete list of its indications and uses.
- The approval of Keytruda for the expanded indication was based on KEYNOTE-859 a randomized, double-blind, placebo-controlled study in 1,579 patients with HER2-negative advanced gastric or GEJ adenocarcinoma who had not previously received systemic therapy for metastatic disease. Patients were randomized to receive Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy, or placebo in combination with chemotherapy. All patients received investigator's choice of chemotherapy (5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin). The major efficacy measure was overall survival (OS). Additional secondary efficacy measures included progression-free survival (PFS) and objective response rate (ORR).
  - Median OS was 12.9 months and 11.5 months for Keytruda plus chemotherapy vs. placebo plus chemotherapy, respectively (hazard ratio [HR] 0.78, 95% CI: 0.70, 0.87; p < 0.0001).</li>
  - Median PFS was 6.9 months and 5.6 months, respectively (HR 0.76, 95% CI: 0.67, 0.85; p < 0.0001).</li>
  - ORR was 51% (95% CI: 48, 55) and 42% (95% CI: 38, 45), respectively (p < 0.0001).</li>
- The recommended dose of Keytruda for the treatment of HER2-negative gastric cancer is 200 mg every 3 weeks or 400 mg every 6 weeks via intravenous infusion, until disease progression, unacceptable toxicity, or up to 24 months. Keytruda should be administered prior to chemotherapy when given on the same day.
  - Refer to the Keytruda drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.